kringle-pharmaCo., Ltd.

NEWS

notice

Dec 03, 2008 Notice

Kringle Pharma Initiated a Phase 2 Clinical Trial in Norway on ChronSeal, a Recombinant Human HGF-Based Therapy for the Treatment of Skin Ulcers.

Kringle Pharma Initiated a Phase 2 Clinical Trial in Norway on ChronSeal®, a Recombinant Human HGF-Based Therapy for the Treatment of Skin Ulcers.